

## Erratum to: Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users

James M. Stone · Fiona Pepper · Johnson Fam ·  
Hannah Furby · Emer Hughes · Celia Morgan ·  
Oliver D. Howes

Published online: 11 December 2013  
© Springer-Verlag Berlin Heidelberg 2013

**Erratum to: Psychopharmacology**  
**DOI 10.1007/s00213-013-3354-8**

It has come to our attention that there is an error in the published version of Table 1 from our recently published paper. The last three rows relating to the CAARMS scores in ketamine users and controls have been switched, incorrectly showing that controls had higher psychopathology scores than ketamine users. A corrected version of the table is provided below.

---

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00213-013-3354-8>.

---

J. M. Stone · J. Fam · O. D. Howes  
Department of Experimental Medicine, Imperial College London,  
London, UK

F. Pepper · H. Furby · C. Morgan  
Clinical Psychopharmacology Unit, University College London,  
London, UK

E. Hughes  
Robert Steiner MRI Unit, Imaging Sciences Unit, Hammersmith  
Hospital, Imperial College London, London, UK

F. Pepper · O. D. Howes  
MRC Clinical Sciences Centre, Hammersmith Hospital,  
Imperial College London, London, UK

J. M. Stone · O. D. Howes  
Department of Psychosis Studies, Institute of Psychiatry,  
King's College London, London, UK

J. M. Stone (✉)  
Centre for Neuroimaging Sciences, Institute of Psychiatry,  
King's College London, London, UK  
e-mail: james.m.stone@kcl.ac.uk

**Table 1** Participant demographics, self-reported drug use and clinician-rated psychotic-like symptoms

	Ketamine Users ( <i>n</i> =15)	Controls ( <i>n</i> =13)	Statistical significance analysis
Age mean(SD)	25.7 (2.1)	24.5 (2.6)	$t=1.3; p=0.2$
Sex (M/F)	9/6	11/2	Chisq=1.03; $p=0.30$
Years of Education mean(SD)	14.9 (3.9)	17.3 (4.1)	$t=1.6; p=0.12$
Smoker (Y/N)	9/6	6/7	Chisq=0.12; $p=0.72$
History of Alcohol use (Y/N)	15/0	13/0	Chisq=N/A; $p=1$
Alcohol units per week mean(SD)	54.3 (80.2)	12.1 (9.2)	$t=1.8; p=0.08$
History of Cannabis (Y/N)	15/0	13/0	Chisq=N/A; $p=1$
Level of cannabis use – days taken to smoke 1/8th ounce cannabis (SD)	9 (17.2)	341 (838)	$t=1.19; p=0.27$
History of MDMA (Y/N)	14/1	9/4	Chisq=1.36; $p=0.24$
MDMA mg per month mean(SD)	2218 (5103)	178 (549)	$t=1.54; p=0.15$
History of Cocaine (Y/N)	15/0	10/3	Chisq=1.84; $p=0.18$
Cocaine g per month mean(SD)	6.3 (8.8)	1.78 (5.7)	$t=1.57; p=0.13$
History of amphetamine use (Y/N)	13/2	8/5	Chisq=1.20; $p=0.27$
Amphetamine g per month mean(SD)	0.6 (0.75)	0	$t=2.77; p=0.02^*$
History of Ketamine (Y/N)	15/0	5/8	Chisq=10.1; $p=0.001^{***}$
Ketamine g per month mean(SD)	100 (114)	0 (0)	$t=3.34; p=0.005^{**}$
CAARMS – severity of abnormalities of thought content mean(SD)	2.33 (1.84)	0.53 (0.88)	$t=3.37; p=0.003^{***}$
CAARMS – severity of perceptual abnormalities mean(SD)	2.26 (1.67)	1.69 (2.01)	$t=0.81; p=0.42$
CAARMS – severity of abnormalities of speech production mean(SD)	2.07 (1.79)	1.38 (1.76)	$t=1.01; p=0.32$

Comprehensive Assessment of At Risk Mental State – CAARMS; \*  $p<0.05$ , \*\*  $p<0.01$ , \*\*\*  $p<0.005$